Gene · 115650
Papers2,634
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
61 to 80 of 2,634
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Bispecific and multispecific T-cell engagers: advancing the future of immunotherapy. | Antib Ther | 2026 | 41561192 | PubTator, text mining | PubMed |
| Antibodies to watch in 2026. | MAbs | 2026 | 41560619 | PubTator, text mining | PubMed |
| Memory B cells mediate the effect of gut microbiota glycolytic-glyoxylate pathway on lung cancer in never-smokers: A Mendelian randomization study. | Medicine (Baltimore) | 2026 | 41560014 | PubTator, text mining | PubMed |
| BAFF-R expression as a potential biomarker associated with COVID-19 vaccine non-responsiveness in antibody-deficient patients. | Clin Exp Immunol | 2026 | 41559870 | PubTator, text mining | PubMed |
| Bicistronic-CD19/22 Chimeric Antigen Receptor T-Cell Therapy for Childhood Refractory Lupus Nephritis. | Kidney Int Rep | 2026 | 41541778 | PubTator, text mining | PubMed |
| Somatic deficiency of the human E3 ubiquitin ligase CBL in leukocytes impairs B cell but not T cell development and function. | Nat Immunol | 2026 | 41540267 | PubTator, text mining | PubMed |
| Effect of Red Blood Cell Transfusion on Inflammatory and Angiogenic Pathways in Patients With Sickle Cell Disease. | Am J Hematol | 2026 | 41492941 | PubTator, text mining | PubMed |
| Bispecific BAFF-R/BCMA CAR T cells control growth of heterogeneous plasma cells in multiple myeloma. | Mol Ther | 2026 | 41376157 | PubTator, text mining | PubMed |
B cell depletion and BAFF receptor blockade with ianalumab (VAY736) for the treatment of moderate-to-severe systemic lupus erythematosus: a phase 2 randomised, double-blind, placebo-controlled trial with subsequent open-label treatment. | Ann Rheum Dis | 2026 | 41353079 | PubTator, text mining | PubMed |
| Belimumab modulates type I interferon signalling in the treatment of systemic lupus erythematosus. | Clin Exp Rheumatol | 2026 | 41328601 | PubTator, text mining | PubMed |
| Immunosuppressive contribution of tumour-infiltrating B cells in human intrahepatic cholangiocarcinoma and their role in chemoimmunotherapy outcome. | Gut | 2026 | 40889886 | PubTator, text mining | PubMed |
| Immunocytes Play a Crucial Role as Mediators in the Protective Effects of D-β-Hydroxybutyrate Dehydrogenase 1 against Type 2 Diabetes Mellitus: A Mendelian Randomization Study | Endocr Metab Immune Disord Drug Targets | 2026 | 40396311 | PubTator, text mining | PubMed |
| Genetically predicted immune cell-mediated causal associations between 473 gut microbiome species and neurodevelopmental disorders. | IBRO Neurosci Rep | 2025 | 41601555 | PubTator, text mining | PubMed |
| BCMA biology and therapeutic targeting in multiple myeloma: From ligand signaling to antigen escape. | Semin Hematol | 2025 | 41539897 | PubTator, text mining | PubMed |
| Differential Transcriptomic Features of Peripheral Blood Mononuclear Cells in Pulmonary Sarcoidosis with and Without Extrapulmonary Lesions in an East Asian Population. | Biomedicines | 2025 | 41463010 | PubTator, text mining | PubMed |
| LONMF: a non-negative matrix factorization model based on graph Laplacian and optimal transmission for paired single-cell multi-omics data integration. | BMC Bioinformatics | 2025 | 41437217 | PubTator, text mining | PubMed |
| Novel allogeneic CAR T-cell platform involving microhomology-mediated end joining repair and low off-targeting potential. | Mol Ther Nucleic Acids | 2025 | 41404500 | PubTator, text mining | PubMed |
| BTLA-Expressing Memory B Cells Are Associated with Belimumab-Induced Improvement in Systemic Lupus Erythematosus. | Int J Mol Sci | 2025 | 41373483 | PubTator, text mining | PubMed |
| Association of Immune Cells, Inflammatory Cytokines, and Lung Cancer: A Mediating Mendelian Randomization Study. | Mediators Inflamm | 2025 | 41292522 | PubTator, text mining | PubMed |
| Addition of Ianalumab (VAY736) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia on Ibrutinib Therapy: Results from a Phase Ib Study. | Clin Cancer Res | 2025 | 41194375 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/115650/papers?page=4